Connect to other sites within the UBM Medica Network
Top 5 Things to Remember About Rhythm Control in AF
When is a rhythm control strategy appropriate? Which patients are candidates for amiodarone? When is AF ablation the answer? Here, a top-line review of rhythm control for atrial fibrillation.
Game Change in the World of Atrial Fibrillation
The absence of an antidote may soon disappear as a reason to avoid prescribing a novel oral anticoagulant to patients with atrial fibrillation, based on promising phase III trial results.
Dabigatran Increases “Real-World” Bleeding
The risk for major bleeding and GI hemorrhage in patients taking dabigatran was greater than in those taking warfarin; warfarin, however, was associated with a greater risk of intracranial hemorrhage.
Amiodarone-warfarin Interaction Ups Risk in ARISTOTLE Patients
In analysis of this randomized controlled trial of apixaban vs warfarin for nonvalvular atrial fibrillation, there was an increased risk of stroke and systemic embolism among patients taking amiodarone and warfarin.
Five Top Papers From 2014 That Will Impact Your Practice
New drugs that treat stubborn illness seen often in primary care lead this group of Top 5 Papers for 2014. Type 2 diabetes, cryptogenic stroke, and hep-C are key targets.
Atrial Fibrillation Video: Symptoms, Cardioversion Strategies
A nurse describes his own bout with atrial fibrillation—the symptoms and his attempts to cardiovert to normal rhythm—from his hospital bed.
Trends in Atrial Fibrillation Therapy: 2002 to 2011
Overall it looks as though pharmacologic rate control is still the preferred therapy for new onset AF, but a new study identifies some interesting trends in the use of drugs for both rhythm and rate.
By clicking Accept, you agree to become a member of the UBM Medica Community.